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Abstract
Background: The rate of acquisition of naturally acquired immunity (NAI) against malaria predominantly depends on
transmission intensity and age, although disentangling the effects of these is difficult. We used chemoprophylaxis to
selectively control exposure to P. falciparum during different periods in infancy and explore the effect of age in the build-up
of NAI, measured as risk of clinical malaria.
Methods and Findings: A three-arm double-blind randomized placebo-controlled trial was conducted in 349 infants born
to Mozambican HIV-negative women. The late exposure group (LEG) received monthly Sulfadoxine-Pyrimethamine (SP) plus
Artesunate (AS) from 2.5–4.5 months of age and monthly placebo from 5.5–9.5 months; the early exposure group (EEG)
received placebo from 2.5–4.5 months and SP+AS from 5.5–9.5 months; and the control group (CG) received placebo from
2.5–9.5 months. Active and passive case detection (PCD) were conducted from birth to 10.5 and 24 months respectively. The
primary endpoint was time to first or only episode of malaria in the second year detected by PCD. The incidence of malaria
during the second year was of 0.50, 0.51 and 0.35 episodes/PYAR in the LEG, EEG and CG respectively (p=0.379 for the
adjusted comparison of the 3 groups). The hazard ratio of the adjusted comparison between the LEG and the CG was 1.38
(0.83–2.28, p=0.642) and that between the EEG and the CG was 1.35 (0.81–2.24, p=0.743).
Conclusions: After considerably interfering with exposure during the first year of life, there was a trend towards a higher risk
of malaria in the second year in children who had received chemoprophylaxis, but there was no significant rebound. No
evidence was found that the age of first exposure to malaria affects the rate of acquisition of NAI. Thus, the timing of
administration of antimalarial interventions like malaria vaccines during infancy does not appear to be a critical determinant.
Trial Registration: ClinicalTrials.gov NCT00231452
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In endemic areas, malaria affects primarily children younger
than 5 years of age and pregnant women. Exposure to repetitive
Plasmodium falciparum infections from birth leads to the develop-
ment of naturally acquired immunity (NAI), which is rapidly
acquired against the most severe forms of malaria, takes longer
against milder forms and is never sterilizing [1]. Young children
are at higher risk until they have developed this semi-immunity,
and pregnant women temporarily lose the capacity to control the
infection [1,2]. Malaria control tools should ideally provide
protection from early infancy and during the most vulnerable
first years without impairing the development of NAI. The
immune mechanisms involved in NAI are not well understood and
immune correlates of protection against P. falciparum have not yet
been identified in young children, the only surrogate of NAI being
the risk of clinical malaria. We know the rate of acquisition of
immunity predominantly depends on the intensity of malaria
transmission and age of exposure, however it is difficult to
disentangle the effects of these two factors and there is no clear
evidence of the age interactions in the development of NAI [3].
Studies in malaria-naı ¨ve transmigrants in Indonesia [4–6]
suggested that a more mature immune system may allow an adult
to acquire immunity more rapidly than a child under the same
conditions of exposure. We hypothesize that the phenomenon of
age-dependent changes in the ability to acquire NAI may also
apply on a reduced time scale during the first year of life.
Previous trials of malaria chemoprophylaxis and vaccines
conducted in Ifakara, Tanzania, suggested that the age of first
exposure to P. falciparum might play an important role in the
development of NAI. Children who received chemoprophylaxis
with DeltaprimH (Pyrimethamine plus Dapsone) from 8 to 48
weeks of age had a lower incidence of severe anaemia and clinical
malaria during the first year of life compared to placebo recipients
[7]. However, during the second year there was a rebound effect
leading to an increased incidence of anaemia and clinical malaria
suggesting that continuous chemoprophylaxis impaired the
development of NAI. An extended follow-up showed that by the
age of 4 years the cumulative rates of severe malaria and severe
anaemia were lower among chemoprophylaxis recipients com-
pared to controls [3]. Therefore, suppressing malaria parasites in
infants during the first year by chemoprophylaxis led to an overall
slightly increased cumulative rate of uncomplicated malaria by the
fourth birthday but this was not associated with an increase in
severity. In a separate trial, intermittent preventive treatment in
infants (IPTi) with Sulfadoxine-Pyrimethamine (SP) given at ages
2, 3 and 9 months through the Expanded Program on
Immunization (EPI) showed a protective efficacy for clinical
malaria and severe anaemia during the first year of life compared
to placebo recipients and there was no rebound effect in malaria or
anaemia during the second year, indicating that development of
NAI was not impaired [8]. Moreover, IPTi-SP produced a
sustained reduction in the risk of clinical malaria during the second
year suggesting that IPTi could actually enhance the development
of NAI [9].
The efficacy provided by continuous and intermittent prophy-
laxis during the first year of life in these two trials was similar; what
differed was the development of NAI, which was impaired in
children receiving continuous chemoprophylaxis for most of the
first year but was not affected in children receiving IPTi. Given
that there is almost no clinical malaria in children younger than 2
months [10–12] and that each dose of IPTi with SP suppressed
parasitaemia over an interval of approximately one month [13],
the main difference between the two trials is that infants in the
IPTi trial were exposed to P. falciparum from 4 to 9 months of age
and infants in the continuous chemoprophylaxis trial were not.
This difference in the age of exposure to the parasite led us to
hypothesise that exposure to erythrocytic-stage antigens of P.
falciparum during the first months of life did not contribute to the
development of NAI, whereas exposure during the second half of
infancy was crucial for the acquisition of NAI.
Two trials of the candidate malaria vaccine Spf66 in the same
area in two different age groups further supported this hypothesis.
Spf66 had an estimated vaccine efficacy (VE) of 31% (95% CI 0–
52%; p=0.046) in children aged 1 to 4 years [14], but a VE of 2%
(95% CI 216–16%, p=0.84) in infants immunized according to
the EPI schedule at 1, 2 and 7 months [15]. Moreover, the
breadth, intensity and longevity of antibody responses against
SPf66 were significantly lower in infants as compared to older
children or adults [16]. These results suggested that the immune
response to the Spf66 vaccine in young infants was qualitatively
different from that in older children. There is indeed evidence to
suggest that immune responses in the newborn are suboptimal but
that there is a potential for enhancement of these responses [17].
Taken together, data from these four trials posed a fundamental
question: is there a critical time window in infancy during which
exposure to P. falciparum enhances adequate development of NAI
whereas exposure outside this window does not? If immune
responses during the first months of life are impaired, would it be
possible to enhance them? This has major implications for infant
immunization with malaria vaccines, regarding both the timing
and type of immunization, and the implementation of other
malaria control tools to be administered during infancy.
Accordingly we used monthly chemoprophylaxis to selectively
control exposure to P. falciparum erythrocytic stage antigens during
different periods in infancy and explored the effect of age of
exposure in the build-up of NAI. The specific objective was to
determine whether exposure to P. falciparum erythrocytic stage
antigens between 0 to 5 months of age, or between 5 to 10 months
of age, affected NAI, measured as the subsequent risk of clinical
malaria between 12 and 24 months of age, as compared to infants
with continuous exposure.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study area
The study was conducted at the Centro de Investigac ¸a ˜o em
Sau ´de de Manhic ¸a (CISM), located in Manhic ¸a, Maputo
Province, southern Mozambique. The area has been described
in detail elsewhere [18]. Transmission of P. falciparum is perennial
with marked seasonality and of moderate intensity, with an
entomological inoculation rate of 38 infective bites/person/year
[19].
CISM runs a demographic surveillance system in its study area
and a morbidity surveillance system at Manhic ¸a District Hospital
(MDH) and other health posts in the area through which
standardized information on all paediatric outpatient visits and
admissions to hospital is collected. Recruitment and follow up of
study participants were done at the Maragra Health Post (MHP),
in the south of the study area, from September 2005 to March
2009.
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The protocol was approved by the National Mozambican Ethics
Review Committee and the Hospital Clinic of Barcelona Ethics
Review Committee. The trial was conducted according to the
ICH Good Clinical Practice guidelines and reviewed by a Local
Safety Monitor (LSM) and a Data and Safety Monitoring Board
(DSMB). The trial was registered in ClinicalTrials.gov (clinical
trials identifier NCT00231452).
Study design and procedures
Recruitment and randomization. The study was designed
as a double-blind randomized placebo-controlled trial (Figure 1).
HIV-negative pregnant women resident in the Manhic ¸a study area
were recruited during the third trimester of pregnancy at the
antenatal clinic. Written informed consent was sought to enrol
their newborn children in the study upon birth. After delivery,
newborns were evaluated for eligibility; inclusion criteria included
a birth weight $2 kg, lack of apparent health problems and
having an alive mother. Exclusion criteria included birth weight
,2 kg, same gender twins, congenital malformations or birth
asphyxia. 349 eligible newborns were enrolled and received a
sequential study number, which assigned them to one of 3 groups
by block randomization (for every 6 newborns, 2 were randomized
to each of the 3 groups), in order to adjust for seasonality of
malaria infection. Study photo identification cards of the couple
child-mother were issued to each study participant. Enrolment
started in September 2005 and finished in March 2007.
Investigators, clinicians involved in surveillance for endpoints,
field workers, laboratory personnel and participants were blinded
to the intervention group.
Chemoprophylaxis groups. Monthly chemoprophylaxis
with SP (FansidarH 500/25 mg) plus Artesunate (AS, ArsumaxH
50 mg) or placebo (provided by Roche and Sanofi-Aventis) was
administered during different periods of the first year of life
according to the randomization group (Figure 1). Group 1 (Late
exposure group) received monthly chemoprophylaxis with SP+AS
from approximately 2.5 to 4.5 months of age (Interventions A, B
and C) and monthly placebo from approximately 5.5 to 9.5
months of age (Interventions D, E, F, G and H). Group 2 (Early
exposure group) received monthly placebo from approximately 2.5
to 4.5 months of age (Interventions A, B and C) and SP+AS
monthly from approximately 5.5 to 9.5 months of age
(Interventions D, E, F, G and H). Group 3 (Control group)
received placebo monthly from approximately 2.5 to 9.5 months
of age (Interventions A to H). Interventions were staggered with
EPI vaccinations (given at 0, 2, 3, 4 and 9 months in Mozambique)
leaving an interval of 2 weeks to avoid possible interactions with
vaccine responses. Interventions were scheduled every 4 weeks,
with intervention A starting at 11 weeks of age. Chemoprophylaxis
was not started in children less than 11 weeks old because of the
risk of kernicterus when administering SP to infants younger than
2 months and the negligible incidence of malaria in this age group
in the study area [11]. Thus, given that the effect of SP+AS was
assumed to last for at least one month, due to the relatively long
half-life of SP [13], infants in the late exposure group were
considered protected from malaria from birth until 5.5 months of
age and exposed to P. falciparum erythrocytic stage antigens from
5.5 months onwards. In contrast, those in the early exposure group
were considered exposed from 2.5 to 5.5 months and protected
from 5.5 months to 10.5 months.
Drugs were administered by a field worker according to the
following age-based dosing schedule: K tablet of SP or placebo
and K tablet of AS or placebo on the first day and K tablet of AS
or placebo on the second and third days. Tablets were crushed,
mixed with water and administered to the child. If the child
vomited, a replacement dose was administered.
During the study, Mozambique’s national first line-treatment
policy for malaria was SP plus Amodiaquine, which was replaced
by SP plus AS in July 2006. Prior to the administration of study
drugs the field worker asked the mother/guardian and checked the
health card to determine whether the child had received
antimalarials during the previous 2 weeks and if so, the study
drugs were not administered to avoid repeating a treatment with
SP.
Follow up. Study participants were followed up until age 24
months. Weekly active case detection (ACD) was conducted from
birth to approximately age 10.5 months (4 weeks after intervention
H) and monthly home visits from 10.5 to 24 months of age. ACD
visits were performed at home by field workers, who measured the
axillary temperature with a digital thermometer and asked the
Figure 1. Study design.
doi:10.1371/journal.pone.0032362.g001
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(axillary temperature $37.5uC) or whose guardians reported
history of fever in the preceding 24 h were taken to MHP, where
they were examined and parasitaemia and haematocrit were
determined. Antimalarials were administered according to
procedures explained below if the slide reading was positive for
asexual Plasmodium parasitaemia. During the monthly visits the
mothers/guardians of the participants were asked about the
occurrence of any serious adverse events (SAEs) since the previous
visit and the residence status was confirmed.
Additionally, passive case detection (PCD) was carried out at
the MHP and MDH through the morbidity surveillance system to
monitor attendances to the outpatient clinics and admissions to
hospital. Parents/guardians of study participants were asked to
take their children to the MHP or MDH should they have any
health problem at any time, where they were managed and
treated according to Mozambican national guidelines by the
attending medical personnel. Standard procedures included
identification of the child, measurement of axillary temperature,
completion of a standard morbidity questionnaire and physical
examination. If the temperature was $37.5uCo rt h e r ew a sa
reported fever in the preceding 24 hours, haematocrit and
malaria parasitaemia were assessed. Antimalarials were admin-
istered only if the blood slide was positive. As first line
antimalarial treatment included SP, study participants who
presented with malaria and had received a study intervention
within the previous 2 weeks received oral quinine (10 mg/kg/8 h
for a minimum of 5 days) for the treatment of their episode.
Children seen at the MHP presenting severity criteria were
transferred to MDH, where they were reassessed and admitted if
necessary. Severe malaria in admitted patients was treated with
parenteral quinine for a minimum of 6 doses, followed by SP or
SP+AS when the first line treatment changed or continued up to
21 doses if given as monotherapy. Children presenting a
haemoglobin (Hb) ,10 g/dL on the full blood counts performed
during the study cross-sectional samplings, were treated with oral
iron for one month.
Safety surveillance of SAEs, including a detailed evaluation of
any skin reactions potentially related to SP, was done through the
PCD and during study visits. When a child presented with a skin
reaction, a specific questionnaire was filled out and pictures of the
lesion were taken and assessed by a study physician. SAEs were
followed up by a study physician and the LSM and the DSMB
reviewed all skin reaction and SAE data. Axillary temperature,
weight and length were measured during five cross-sectional
surveys at approximately 2.5 months of age (cross-sectional 1, at
the intervention A visit), 5.5 months (cross-sectional 2, at the
intervention D visit), 10.5 months (cross-sectional 3, 4 weeks after
intervention H), 15 months (cross-sectional 4) and 24 months
(cross-sectional 5).
Blood sampling. Blood samples were collected at delivery,
during each cross-sectional survey, at the first clinical malaria
episode and one month later. At delivery, the following samples
were collected: 10 mL of peripheral venous blood (into an EDTA
vacutainer), two blood slides and two drops of blood on filter paper
from the mother, 8 mL of blood (into an EDTA vacutainer) and
two drops of blood on filter paper from the cord, and a sample of
placental tissue. When the delivery occurred outside the maternity,
only the mother’s sample was collected during the enrolment visit.
During the cross-sectional visits, a 1 mL blood sample was
collected into EDTA microtainers by finger-prick, blood spots
were also collected on filter paper at cross-sectional visits 1 and 5
to determine parasitaemia by PCR and two blood smears were
collected at visit 5.
Laboratory methods
Blood slides were read to quantify parasitaemia following
standard quality-controlled procedures at the CISM laboratory.
Blood films were air-dried, Giemsa-stained, and examined using a
light microscope fitted with a 1006oil immersion lens and a 106
eyepiece. Parasite density was assessed by counting the number of
asexual stage parasites until 500 leukocytes or parasites had been
counted. Slides were declared negative only after 2000 leukocytes
had been counted. Parasite numbers were converted to a count/
mL by assuming a standard leukocyte count of 8000/mL. All sides
were read by two independent microscopists and a third reading
was performed if there was discrepancy in positivity or the ratio of
densities from the two readings was more than 1.5 or the absolute
difference was .10 parasites/mL. The final result was based on the
definitive verdict for positivity or on the geometric mean of the
positive densities for positive slides. Haematocrit was measured in
heparinised microcapillary tubes with a Hawksley haematocrit
reader (Hawksley & Sons Ltd, Lancing, UK) after centrifugation
with a microhaematocrit centrifuge. Full blood counts were
performed using a Sysmex KX-21N cell counter (Sysmex
Corporation, Kobe, Japan). Tissue samples were collected from
the maternal side of the placenta and placed into 10% neutral
buffered formalin. Biopsies were processed and analyzed following
standard procedures to evaluate presence of parasites or pigment
in the placenta [20]. Real-time quantitative PCR to detect P.
falciparum was conducted with filter paper samples as previously
described [21].
Sample size
Based on results from a previous chemoprophylaxis trial [7], it
was estimated that using a two-tailed test with a=5%, 78 children
per group would be needed to have 80% power to detect a relative
risk of 2 in the Early exposure group as compared to the Late
exposure group for at least one clinical malaria episode in the
second year of life, and to detect a relative risk of 2 in the Early
exposure group as compared to the Control group, assuming an
incidence of clinical malaria of 0.4 episodes per person-year at risk
(PYAR). To account for a 20% loss of follow up 98 children per
group were needed. Sample size calculation was done using Stata
software 7 (College Station, TX, USA) according to previously
described methods [22]. Nevertheless, the incidence of clinical
malaria in study participants during the first year of the study was
lower than expected and the sample size of the study was increased
to 117 participants per group to increase the power of the study.
Data management and statistical methods
Randomization was done at CISM using Stata software 7
(College Station, TX, USA) by a statistician who was not involved
in other study procedures. The code was kept by the DSMB and
released to the investigators once databases had been cleaned and
locked after completion of follow-up. Questionnaires were double
entered into databases using a program written in Fox Pro
(Microsoft Corp., Seattle, WA, USA) at CISM.
The primary case definition of a clinical malaria episode was
measured axillary temperature $37.5uC or history of fever within
the prior 24 hours plus the presence of P. falciparum asexual stage
parasites of any density. Secondary case definitions included
different parasitaemia cut-offs. Moderate and severe anaemia was
defined as Hb ,8 g/dL or haematocrit ,25% if Hb results were
not available. An intervention was defined as completed if the first
day and the second and/or third day of the intervention were
completed without vomiting and the interval since the previous
intervention was of 3–6 weeks. The intervention was also
considered complete if the study intervention was not administered
Age, Exposure and Immunity to Malaria in Infants
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the previous 2 weeks.
The according-to-protocol (ATP) cohort included children who
completed .=75% of the interventions ($6 of 8 interventions
completed), and should there be 2 missing interventions these
should not be consecutive and should not be both in the first 3
months (interventions A to C). The Total cohort included children
who had received at least one intervention and the intention-to-
treat (ITT) cohort included all randomized children.
Analyses were performed according to a predefined analytical
plan using Stata/SE 10.1 (College Station, TX, USA). The
primary endpoint of the study was the time to first or only episode
of clinical malaria (according to the primary case definition) in
the second year of follow up detected by PCD in the ATP cohort.
The global comparison between the 3 groups and pairwise
comparisons of the 3 groups are presented. Secondary endpoints
included different case definitions, including multiple episodes of
malaria, time to first or only episode of anaemia, total hospital
visits and prevalence of parasitaemia and anaemia at different
time points. Analyses were also performed in the Total and ITT
cohorts and exploratory endpoints included time to first or only
episode of clinical malaria during the different intervention
periods of the first year of life detected by ACD or PCD in the
ATP cohort.
Time at risk was calculated as the number of PYAR from the
date or expected date of intervention A until the end of follow-up,
migration, death or withdrawal of consent, whichever occurred
first. An arbitrary lag period of 28 days was applied after a case of
clinical malaria, during which children did not contribute to the
time at risk. In the ATP cohort, children who were absent from the
study area for .3 months did not contribute to the time at risk
after the migration date.
Cox regression was used to evaluate the effect of the study
intervention on the risk of first or only clinical malaria or anaemia
episode. Negative binomial regression was used to evaluate the
effect of the intervention on the incidence of multiple malaria
episodes and total hospital visits. Logistic regression was used to
compare prevalences. In the ATP cohort, the intervention effect
was adjusted for use of insecticide treated nets (ITNs), indoor
residual spraying (IRS), exclusive breastfeeding at 5.5 months,
birth weight (Kg) and gender. Missing values in continuous
covariates were imputed using the prediction from the best
available subset of present data (determined by best-subset
regression) in order to avoid losing observations and to compare
the crude and adjusted models [23,24].
Continuous variables were compared by ANOVA and
categorical variables were compared by Chi-squared test or
Fisher’s exact test, as appropriate. The global comparison of the
interventions was evaluated using a likelihood ratio test and a
global p-value for significance. To control for family-wise error,
the Bonferroni correction for multiple testing was applied to the p-
values from pairwise comparisons between intervention groups.
Transformation of child anthropometric data to z-scores were
performed using the LMS method [25] and the reference data
available from the 2000 CDC Growth Reference in the U.S. [26].
Results
Three hundred and forty-nine children were recruited and
randomized into 3 groups (early exposure, late exposure and
control). Figure 2 shows the trial profile. The groups were
Figure 2. Trial profile.
doi:10.1371/journal.pone.0032362.g002
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children (Table 1 and Table 2), except for IRS of the household in
the preceding year, that was higher for the late exposure group.
Controlling the age of first exposure was successfully achieved
with highly efficacious SP+AS chemoprophylaxis, as shown by the
incidence of malaria during the intervention periods. The
incidence of malaria in the late exposure group during the first
intervention period (from intervention A to one month after
intervention C) was 0 (0 episodes/23.97 PYAR) and in the early
exposure group during the second intervention period (from
intervention D to one month after intervention H) was 0.06 (2
episodes/35.72 PYAR). Figure 3A shows the Kaplan-Meier curve
for the cumulative proportion of children who had at least one
episode of malaria (primary case definition) by group during the
first year in the ATP cohort.
There were 98 first episodes of clinical malaria meeting the
primary case definition during the second year of life in the ATP
cohort (36, 34 and 28 in the late exposure, early exposure and
control groups respectively), yielding incidences of 0.50, 0.51 and
0.35 episodes per PYAR respectively, which were not significantly
different between the 3 groups (p=0.261 for the crude overall
comparison of the 3 groups and p=0.379 for the adjusted
comparison; Table 3). The hazard ratio of the adjusted
comparison between the late exposure and the control group
was 1.38 (95% CI 0.83–2.28, p=0.642) and that between the
early exposure and the control group was 1.35 (95% CI 0.81–
2.24, p=0.743; Table 4), but showed no significance. Figure 3B
shows the Kaplan-Meier curve for the cumulative proportion of
children who had at least one episode of malaria (primary case
definition) by group during the second year of follow up in the
ATP cohort.
Table 3 presents the incidences and global comparison between
the 3 groups for secondary malaria case definitions, anaemia and
total outpatient visits and hospital admissions, showing no
significant difference for any of the comparisons. Table 4 presents
the pairwise comparisons. For the more specific case definitions
the incidence was highest in the early exposure group, but none of
the comparisons were significant. The analysis of the ITT and
Total cohort yielded very similar results (data not shown).
The prevalence of parasitaemia by microscopy at the last cross-
sectional sampling (24 to 26 months of age) also showed no
differences between the three groups (13.04%, 13.95% and 7.45%
in the late exposure, early exposure and control groups
respectively, p=0.302; Table 5). Table 5 also presents the
prevalence of anaemia, mean Hb, geometric mean parasitaemia
and anthropometric measures at the last cross-sectional visit in the
ATP cohort, for which there were no differences between the
groups. Pairwise comparisons also showed no significant differ-
ences for these outcomes (data not shown).
There were no safety concerns during the trial. There were 62
skin reactions during the intervention period (up to one month
from last dose) in the total cohort, but only one (urticaria with
pruritus) was assessed to be possibly related to the intervention and
all resolved without sequelae. The occurrence of SAEs was
similarly distributed among the groups, and none was deemed
related to study drugs. There were 5 deaths during the complete
follow up, none considered related to the intervention and 3
occurring in children who had not yet received an intervention.
Table 1. Baseline characteristics of mothers at delivery of the three study groups in the ATP cohort.
Mother’s variables Intervention group p-value
Late exposure Early exposure Control
Age (years)
1 25.1 (7.1) [102] 24.3 (7.0) [92] 24.9 (6.4) [101] 0.714
2
Parity
3 Primigravidae 19 (18.6%) 23 (25.0%) 27 (26.2%) 0.726
6
Multigravidae 73 (71.6%) 62 (67.4%) 68 (66.0%)
Unknown 10 (9.8%) 7 (7.6%) 8 (7.8%)
Haemoglobin (g/dL)
1 11.4 (2.4) [80] 11.3 (2.4) [80] 11.1 (2.2) [86] 0.727
2
Peripheral P.falciparum parasitemia by
microscopy
3
No 93 (91.2%) 81 (88.0%) 95 (94.0%) 0.221
4
Yes 7 (6.9%) 10 (10.9%) 3 (3.0%)
Unknown 2 (1.9%) 1 (1.1%) 3 (3.0%)
Peripheral P.falciparum parasitemia by PCR
3 No 73 (71.6%) 73 (79.3%) 77 (76.2%) 0.670
4
Yes 27 (26.5%) 18 (19.6%) 21 (20.8%)
Unknown 2 (1.9%) 1 (1.1%) 3 (3.0%)
Parasite density (parasites/mL)
5 7693.5 (20357.9) [7] 2473.9 (7149.5) [10] 1079.5 (2974.7) [3] 0.552
2
Placental infection (histology)
3 Not infected 58 (56.9%) 60 (65.2%) 72 (71.3%) 0.072
4
Past Infection 16 (15.7%) 15 (16.3%) 11 (10.9%)
Acute Infection 0 (0%) 3 (3.3%) 1 (1.0%)
Chronic Infection 0 (0%) 1 (1.1%) 1 (1.0%)
Unknown 28 (27.4%) 13 (14.1%) 16 (15.8%)
1: Arithmetic Mean (SD) [n].
2: ANOVA.
3: n (%).
4: Fisher’s exact test.
5: Geometric Mean (SD).
6: Chi-squared test.
doi:10.1371/journal.pone.0032362.t001
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This study used monthly antimalarial chemoprophylaxis to
control exposure to the erythrocytic-stage antigens of the Plasmodium
parasite. By selectively administering chemoprophylaxis to children
during different periods of their first year of life, we evaluated the
importance of age of first exposure to malaria in the development of
NAI during infancy. NAI was measured as incidence of clinical
malaria during the second year of life, as there are no surrogate
markers of protection for P. falciparum, and comparing clinical
malaria between groups is the only way to evaluate acquisition of
immunity. Our hypothesis was that exposure to malaria during the
first months of life would not lead to acquisition of NAI, while
exposure during the second half of infancy would lead to and play a
crucial role in the development of NAI.
Compliance with study drugs among participants was high, and
chemoprophylaxis was well tolerated and highly efficacious, as
proven by the near zero incidence of malaria during the different
time periods in which children received SP+AS. Therefore, from
two to twelve months of age the time of exposure to the parasite
was decreased by 50% in the early exposure group and by 30% in
the late exposure group compared to the control group. However,
we did not find any significant differences in the outcomes between
the three different study groups. Indeed, there were no significant
differences between the groups in the incidence of clinical malaria,
anaemia, total outpatient visits or hospital admissions during the
second year of life. Also, there were no differences in the
prevalence of parasitaemia or anaemia at the end of follow up.
Although the incidence of malaria during the second year was
higher by about 40% in the late exposure and early exposure
groups when compared to the control group, and the risk of
malaria was highest in the early exposure group for the more
specific case definitions, none of these differences reached
statistical significance. The sample size had been calculated to
detect a relative risk of 2 between the groups, based on results from
a previous continuous chemoprophylaxis trial [7]; however, the
observed differences were lower and the study was underpowered
to evaluate the significance of the observed estimate of 1.4. Hence,
the differences seen between the groups might reflect a real
difference that would only be significant with a much larger
sample size or a higher transmission intensity.
Our hypothesis was based on results from previous malaria
chemoprophylaxis and vaccine trials conducted in Tanzania in
infants and young children. Data showed that infants receiving
IPTi [8] but not those on continuous chemoprophylaxis up to 11
months of age [7] were able to develop protective immunity.
However, the long-term follow-up of participants in the latter trial
showed that, although there was a rebound effect in the second
Table 2. Baseline characteristics of children in the three study groups in the ATP cohort.
Children’s variables Intervention group
Late exposure (n=102) Early exposure (n=92) Control (n=103) p-value
Gender
1 Male 53 (52.0%) 44 (47.8%) 51 (49.5%) 0.845
2
Female 49 (48.0%) 48 (52.2%) 52 (50.5%)
Birth season Dry 37 (36.3%) 30 (32.6%) 34 (33.0%) 0.836
2
Wet 65 (63.7%) 62 (67.4%) 69 (67.0%)
Age at intervention A (months)
3 2.6 (0.1) 2.6 (0.1) 2.6 (0.1) 0.658
4
Birthweight (Kg)
3 2.99 (0.42) 2.98 (0.46) 3.02 (0.38) 0.788
4
Exclusive breastfeeding at
cross-sectional 2 (5.5 months)
1
No 53 (52.0%) 56 (60.9%) 64 (62.1%) 0.385
2
Yes 47 (46.1%) 32 (34.8%) 36 (35.0%)
unknown 2 (1.9%) 4 (4.3%) 3 (2.9%)
Use of ITNs
1 No 93 (91.2%) 79 (85.9%) 93 (90.3%) 0.449
2
Yes 9 (8.8%) 13 (14.1%) 10 (9.7%)
Indoor residual spraying
1 No 46 (45.1%) 49 (53.3%) 64 (62.1%) 0.050
2
Yes 56 (54.9%) 43 (46.7%) 39 (37.9%)
Num. of clinical malaria
episodes before intervention A
1
No 102 (100%) 91 (98.9%) 101 (98.1%) 0.530
5
Yes 0 (0%) 1 (1.1%) 2 (1.9%)
P.falciparum parasitaemia by
PCR at cross-sectional 1 (2.5 months)
No 87 (86.1%) 77 (86.5%) 87 (85.3%) 0.969
6
Yes 14 (13.9%) 12 (13.5%) 15 (14.7%)
Weight for length z-score at cross-sectional 1 (2.5 months)
3 0.73 (1.34) [101] 0.52 (1.65) [87] 0.54 (1.31) [99] 0.527
4
Weight for age z-score at cross- sectional 1 (2.5 months)
3 0.30 (0.94) [101] 0.27 (1.26) [88] 0.44 (1.00) [102] 0.479
4
Length for age z-score at cross- sectional 1 (2.5 months)
3 20.55 (1.15) [101] 20.51 (1.16) [89] 20.33 (1.17) [101] 0.332
4
1: n (%).
2: Chi-squared test.
3: Arithmetic Mean (SD) [n].
4: ANOVA.
5: Fisher’s exact test.
6: Log regression model using likelihood ratio test.
doi:10.1371/journal.pone.0032362.t002
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four years was actually lower in children that received chemopro-
phylaxis during most of the first year [3]. Indeed, in the last few
years there has been a debate around interference of the
development of NAI due to interventions and rebound effect
[3]. In our study, despite significantly decreasing exposure to the
parasite during the first year of life, we did not see a significant
impact on the incidence of malaria during the second year.
Nevertheless, there was a trend towards rebound in the second
year, but even if the hazard ratios of 1.4 observed between the late
or early exposure and the control group were significant, the
rebound effect would be much lower than that anticipated based
on previous results [7]. Therefore, a massive reduction in
exposure, such as that obtained with continuous chemoprophy-
laxis during most of the first year, seems to be necessary to see a
rebound, suggesting that a few infections are enough to build NAI,
although this rebound in the second year did not have an impact
in an increased rate of severe disease in the long term [3].
Taking together the results of the three trials, data suggest that
contact with the parasite is needed at some point during infancy to
be able to develop NAI, but that the timing of the exposure does
not seem to be a major contributing factor. Clearly, no differences
in the incidence of malaria during the second year were seen
between the early and late exposure groups, and young infants
with relatively immature immune systems and low exposure were
able to build NAI as well as older infants. With available data it is
not possible to establish the amount of exposure that is needed for
the development of NAI, although exposure in our trial and in the
Tanzanian IPTi trial varied from 5 to 7 months (from 2 to 12
months of age). Infants in these two trials received comparable
challenge during the first year (the incidence of multiple malaria
episodes during the first year was 0.33 episodes per PYAR in the
control group in the former (data not shown) and 0.43 in the latter
[8]), but it is difficult to compare the amount of exposure in both
studies. SP, that was used for IPTi, had a much lower efficacy than
SP+AS, which was highly efficacious at the time of the study in
Figure 3. Kaplan Meier survival curves for cumulative proportion of children who had at least one episode of malaria (primary case
definition) by group in the ATP cohort A) during the first year and B) during the second year of follow up.
doi:10.1371/journal.pone.0032362.g003
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in Mozambique at the time of the study, so it is possible that it was
at some point breached by resistant parasites. Nevertheless, should
this have happened, the duration of the parasitaemia would have
been short, as the monthly administration of AS would have
probably cleared the parasites. Thus children in our trial probably
had a very low exposure to blood-stage malaria antigens while
receiving chemoprophylaxis, whereas it has been argued that SP in
the IPTi trial could have acted as a leaky vaccine, allowing
exposure to low dose parasitaemias in study participants [9].
Overall, no evidence was found that the age of first exposure to
the parasite during the first year of life affects the rate of
acquisition of NAI against malaria. Thus the timing of
administration of antimalarial interventions like malaria vaccines
during infancy does not appear to be a critical determinant, as
infants should be equally able to mount an adequate immune
Table 3. Incidences of the main outcomes during the second year of follow up in the ATP cohort (adjusted analysis).
Late exposure
group (n=100)
Early exposure
group (n=90)
Control group
(n=102) p-value
$
Outcomes Episodes PYAR Incidence Episodes PYAR Incidence Episodes PYAR Incidence
First episode of clinical malaria (fever
or history of fever) with .0 parasites/mL
36 72.66 0.50 34 66.58 0.51 28 80.53 0.35 0.379*
All episodes of clinical malaria
with .0 parasites/mL
88 90.05 0.98 91 80.12 1.14 79 92.59 0.85 0.833
#
First episode of clinical malaria
with .500 parasites/mL
27 79.18 0.34 32 68.27 0.47 23 84.38 0.27 0.231*
First episode of clinical malaria
with .2500 parasites/mL
27 79.18 0.34 31 68.33 0.45 23 85.32 0.27 0.282*
First episode of clinical malaria
with .15000 parasites/mL
20 83.92 0.24 27 71.22 0.38 21 86.38 0.24 0.244*
First episode of moderate or
severe anaemia
13 89.10 0.15 10 81.50 0.12 13 92.01 0.14 0.848*
Total outpatient visits 365 69.73 5.23 334 62.40 5.35 338 74.34 4.55 0.335
#
Total hospital admissions 18 95.21 0.19 17 85.42 0.20 18 97.00 0.19 0.910
#
PYAR: person-years at risk.
$Adjusted by use of ITNs, indoor residual spraying, exclusive breastfeeding at 5.5 months, birthweight (kg) and gender.
*p-value from Cox regression model using Likelihood Ratio Test.
#p-value from negative binomial regression model using Likelihood Ratio Test.
doi:10.1371/journal.pone.0032362.t003
Table 4. Pairwise comparisons between groups of the main outcomes during the second year of follow up in the ATP cohort
(adjusted analysis).
Late exposure vs.
control group
Early exposure vs.
control group
Early vs. late
exposure group
Outcomes HR or IRR
$ 95% CI p-value
& HR or IRR
$ 95% CI p-value
& HR or IRR
$ 95% CI p-value
&
First episode of clinical malaria (fever
or history of fever) with .0 parasites/mL
1.38 0.83–2.28 0.642* 1.35 0.81–2.24 0.743* 0.98 0.61–1.59 1.000*
All episodes of clinical malaria
with .0 parasites/mL
1.14 0.57–2.26 1.000
# 1.23 0.62–2.44 1.000
# 1.08 0.54–2.16 1.000
#
First episode of clinical malaria
with .500 parasites/mL
1.22 0.69–2.16 1.000* 1.60 0.93–2.75 0.273* 1.31 0.77–2.21 0.959*
First episode of clinical malaria
with .2500 parasites/mL
1.23 0.70–2.17 1.000* 1.55 0.90–2.68 0.343* 1.26 0.74–2.15 1.000*
First episode of clinical malaria
with .15000 parasites/mL
0.92 0.49–1.71 1.000* 1.47 0.82–2.62 0.581* 1.60 0.89–2.89 0.359*
First episode of moderate
or severe anaemia
1.16 0.52–2.59 1.000* 0.91 0.40–2.11 1.000* 0.79 0.34–1.82 1.000*
Total outpatient visits 1.15 0.92–1.44 0.666
# 1.16 0.93–1.46 0.549
# 1.01 0.81–1.27 1.000
#
Total hospital admissions 1.14 0.50–2.62 1.000
# 1.19 0.52–2.69 1.000
# 1.04 0.46–2.36 1.000
#
95% CI: 95% confidence interval.
$Hazard ratio (HR) or incidence rate ratio (IRR) adjusted by use of ITNs, indoor residual spraying, exclusive breastfeeding at 5.5 months, birthweight (kg) and gender.
&p-values corrected by Bonferroni.
*p-value from Cox regression model using Likelihood Ratio Test.
#p-value from negative binomial regression model using Likelihood Ratio Test.
doi:10.1371/journal.pone.0032362.t004
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recent results from phase I/IIb trials of the RTS,S/AS0 candidate
malaria vaccine conducted in endemic areas of Africa support this.
In the RTS,S/AS0 trials performed after our trial had started, VE
was similar in three trials in which the vaccine was administered to
infants at different ages: 10, 14 and 18 weeks of age, staggered with
EPI vaccines (VE against infection 65.9, 95% CI 42.6–79.8;
p,0.0001) [28]; at 8, 12 and 16 weeks of age together with EPI
vaccines (VE against infection 65.2, 95% CI 20.7–84.7; p=0.01)
[29]; and at 5 to 17 months (VE against clinical malaria 53%, 95%
CI 28–69, p,0.001) [30]. Vaccine efficacy in these infant trials was
similar or higher to that in children aged 1 to 4 years (VE against
infection 45.0, 95% CI 31.4–55.9; p,0.0001 and VE against
clinical malaria 29.9%, 95% CI 11.0–44.8; p=0.004) [19,31].
Although the potent GSK Biological’s AS0 adjuvants with which
RTS,S was formulated in these trials could have played a role in
overcoming possible suboptimal immune responses in young
infants, it appears the vaccine can also be significantly protective
innewbornswithimmature immunesystems. This confirmsthat the
administration of malaria vaccines through the EPI would be the
best choice to maximize compliance and decrease logistic costs.
Secondaryobjectivesof the studyincludedassessment of type and
quality of immune responses, oxidative stress markers and host
genetic factors, aiming at describing these outcomes according to
age of first exposure and correlating them with clinical malaria
during the second year of life. Results of these analyses will be
presented in other specific papers and will hopefully shed light on
the age-dependency of the immune responses and how those
correlate with protection or susceptibility against malaria. Any step
towards better understanding the development of NAI in infancy
will enhance our chances of improving the current preventive tools
and strategies against this deadly parasite.
Therefore, from this study we can reasonably conclude that no
evidence was found that the age at which the first encounter with
the parasite occurs during infancy is a key determinant in the build
up of immunity. Secondly, considerable reductions in exposure to
parasite antigens in the first year of life do not result in large
rebound in the incidence of malaria during the second year and
massive reductions in exposure are needed to see a significant
impact on the acquisition of NAI.
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